LOGIN  |  REGISTER
Assertio

Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2024 Results: August 8, 2023

July 10, 2023 | Last Trade: US$77.24 0.06 0.08

BOSTON, July 10, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2024 financial results at 6:00 am ET on Tuesday, August 8, 2023. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 8, 2023.

The call can be accessed via teleconference at: Q1 2024 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.

A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link:https://edge.media-server.com/mmc/p/y8b7kg5q 

A replay of the conference call and webcast will be available for one year beginning on August 8, 2023 at 11:00 am ET using the conference call webcast link provided in this press release.

ABOUT HAEMONETICS

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:

 

Olga Guyette, Sr. Director-Investor Relations & Treasury

David Trenk, Manager-Investor Relations

(781) 356-9763

(203) 733-4987

This email address is being protected from spambots. You need JavaScript enabled to view it.

 This email address is being protected from spambots. You need JavaScript enabled to view it.  

Media Contact:

 

Josh Gitelson, Director-Global Communications

 

(781) 356-9776

 

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB